Medicenna Therapeutics Corp.

MDNA

CA58490H1073

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 12:37:53 16/05/2024 am IST			5-day change	1st Jan Change
2.48 ^CAD	-3.12%		-5.34%	+490.48%

13/05	Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee	MT
13/05	Medicenna Brief: Providing Update on its Presentations at the 2024 ASCO Annual Meeting	MT

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

April 30, 2024

On April 30, 2024, Medicenna Therapeutics Corp. closed the transaction. The company has received $14,550,000 (CAD 20,000,430) from single investor pursuant to exemption provided under Regulation D.

Latest news about Medicenna Therapeutics Corp.

Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee	13/05	MT
Medicenna Brief: Providing Update on its Presentations at the 2024 ASCO Annual Meeting	13/05	MT
Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.	30/04	CI
Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding	26/04	CI
Medicenna Therapeutics Up 13% After Flagging Presentations	24/04	MT
Transcript : Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM	16/04
Medicenna Brief: Presenting Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of Phase 1/2 ABILITY-1 Study at 2024 Annual Meeting of the AACR	10/04	MT
Medicenna Therapeutics Presents Separate Updated Results and Preclinical Data; Shares Lost Near 12% Today	10/04	MT
Medicenna Brief: Comes After Its Shares Lost Near 12% today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And Masked Bi-Functional Anti-PD1-IL2 Superkine	10/04	MT
Medicenna Brief: Says Presented Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study	10/04	MT
Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study	10/04	CI
Medicenna Therapeutics Down 11% as it Presents Updated Preclinical Data on MDNA113 at AACR 2024	09/04	MT
Medicenna Brief: Says to Provide Clinical Update on MDNA11 ABILITY-1 Trial at Upcoming American Association for Cancer Research Annual Meeting	06/03	MT
Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting	06/03	CI
Medicenna Reports Q3 Net Loss $5.0 Million	14/02	MT
Medicenna Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Medicenna Brief: Net loss for the quarter ended December 31, 2023, was $5.0 million or ($0.07) per share compared to a net loss of $1.1 million or ($0.02) per share for the quarter ended December 31, 2022	14/02	MT
Medicenna Says First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda in Patients with Advanced Solid Tumors	13/02	MT
Medicenna Brief: Announcing First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Solid Tumors	13/02	MT
Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors	13/02	CI
Medicenna Commences Enrollment in ABILITY-1 Study Combining MDNA11 with Pembrolizumab	09/01	MT
Medicenna Brief: Commencing Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab	09/01	MT
Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck?s Pembrolizumab	09/01	CI
Medicenna Therapeutics Extends Period to Exercise Certain Warrants; Down 1.2%	23/12	MT
Medicenna Therapeutics Extends Period to Exercise Certain Warrants	22/12	MT

Chart Medicenna Therapeutics Corp.

Duration

Period

More charts

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Companyâs IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Companyâs early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.

Sector

Biotechnology & Medical Research

Calendar

01/06/2024 - American Society of Clinical Oncology Annual Meeting - Abstract No: 2709

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.56 CAD

Average target price

7 CAD

Spread / Average Target

+173.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MEDICENNA THERAPEUTICS CORP.	+490.48%	14Cr
MODERNA, INC.	+29.54%	4.92TCr
IQVIA HOLDINGS INC.	+0.98%	4.21TCr
LONZA GROUP AG	+50.47%	4.04TCr
CELLTRION, INC.	-5.26%	2.89TCr
ICON PUBLIC LIMITED COMPANY	+13.66%	2.61TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.71%	1.87TCr
BIO-TECHNE CORPORATION	+8.22%	1.33TCr
MEDPACE HOLDINGS, INC.	+32.23%	1.23TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.91%	1.2TCr

Other Biotechnology & Medical Research